ADMA - ADMA Biologics - Stock Price & Dividends

ADMA Biologics Inc. is a biopharmaceutical company that specializes in developing, manufacturing, and marketing life-changing biologics derived from human plasma. These biologics are designed to treat immune deficiencies and infectious diseases, improving the lives of patients around the world.

The company's portfolio includes BIVIGAM, a treatment for primary humoral immunodeficiency (PI), a condition where the body's immune system is unable to produce enough antibodies to fight infections. ASCENIV, another IVIG product, is also used to treat PI, providing patients with a vital defense against infections. Additionally, ADMA Biologics offers Nabi-HB, a treatment for acute exposure to Hepatitis B, helping to prevent the spread of this serious liver infection.

ADMA Biologics is committed to innovation, with a robust pipeline of plasma-derived therapeutics in development. One of its key areas of focus is the prevention and treatment of S. pneumonia infection, a leading cause of serious illness and death worldwide. By leveraging its expertise in plasma-derived biologics, the company aims to create new treatments that address significant unmet medical needs.

In addition to its product development and manufacturing capabilities, ADMA Biologics operates a network of source plasma collection facilities, ensuring a steady supply of high-quality plasma for its life-saving biologics. The company's products are distributed through a network of independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers, making them accessible to patients who need them most.

Founded in 2004, ADMA Biologics is headquartered in Ramsey, New Jersey, and is dedicated to improving global health through its innovative biologics. For more information, visit https://www.admabiologics.com.